Not Yet RecruitingNCT06546384
Study of semaglutide, alcohol use and liver health in people with obesity
About this title
GLP-1 RA on Alcohol Consumption, Metabolism and Liver Parameters in Patients With Obesity and Fatty Liver Disease
Read the official source — NCT06546384Medication studyAges 18–80SwitzerlandAddiction
Understand this study
Who could participate?
Listed age limits: 18 years to 80 years.
- Listed locations
- BernSee all locations and recruitment
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateEstimated: November 1, 2026
- Recruitment status
- Not Yet Recruiting
- Enrollment listed in the registry
- 64
- Sponsor
- Insel Gruppe AG, University Hospital Bern
- Sponsor type
- Hospital / academic medical center
- Study type
- Behavioral
- Intervention type
- Psychotherapy / behavioral intervention, Medication / drug
- Study phase
- Not clearly listed
- Locations
- Switzerland
- Age range
- From 18 Years to 80 Years
- Official registry ID
- NCT06546384
- Official title
Show the full official title
Effect of Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RA) on Alcohol Consumption, Metabolism and Liver Parameters in Patients With Obesity and Fatty Liver Disease
Recruitment & locations
Not yet recruitingBern
A listed location does not confirm current availability.
Questions about this study
Who is behind this study?
The study sponsor is Insel Gruppe AG, University Hospital Bern, a hospital or academic medical center.
Does this study involve medication?
Yes. The study involves medication, including Semaglutide.
Who can participate?
Listed age limits: 18 years to 80 years.
Is this study still recruiting?
The registry lists this study as not yet recruiting.
